Bausch + Lomb (NYSE:BLCO) Price Target Raised to $17.00

Bausch + Lomb (NYSE:BLCO - Get Free Report) had its price objective boosted by stock analysts at Evercore ISI from $16.50 to $17.00 in a research note issued on Thursday, Benzinga reports. The firm presently has an "in-line" rating on the stock. Evercore ISI's price target suggests a potential upside of 5.13% from the stock's previous close.

BLCO has been the subject of a number of other reports. Wells Fargo & Company lifted their price objective on Bausch + Lomb from $21.00 to $23.00 and gave the stock an "overweight" rating in a research report on Thursday, February 22nd. Evercore lowered their price objective on Bausch + Lomb from $17.00 to $16.50 and set an "in-line" rating for the company in a research report on Thursday, February 22nd. Barclays lifted their price objective on Bausch + Lomb from $17.00 to $18.00 and gave the stock an "equal weight" rating in a research report on Monday, February 26th. Stifel Nicolaus assumed coverage on Bausch + Lomb in a research report on Tuesday, December 12th. They set a "hold" rating and a $16.00 target price for the company. Finally, Royal Bank of Canada set a $20.00 target price on Bausch + Lomb and gave the stock an "outperform" rating in a research report on Friday, December 29th. Five analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $19.68.

Bausch + Lomb Price Performance

Shares of NYSE BLCO traded down $0.32 during midday trading on Thursday, reaching $16.17. 363,306 shares of the company traded hands, compared to its average volume of 443,808. The firm has a market cap of $5.68 billion, a PE ratio of -22.23, a PEG ratio of 1.59 and a beta of 0.36. The stock's 50-day simple moving average is $15.66 and its 200-day simple moving average is $15.92. Bausch + Lomb has a 12 month low of $13.62 and a 12 month high of $21.95. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.09 and a current ratio of 1.74.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings data on Wednesday, February 21st. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.17 by $0.07. Bausch + Lomb had a positive return on equity of 3.70% and a negative net margin of 6.27%. The company had revenue of $1.17 billion during the quarter, compared to analysts' expectations of $1.11 billion. During the same period last year, the business earned $0.23 earnings per share. The business's revenue was up 17.8% on a year-over-year basis. As a group, equities analysts anticipate that Bausch + Lomb will post 0.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bausch + Lomb

Several institutional investors have recently bought and sold shares of the company. Quadrature Capital Ltd boosted its holdings in shares of Bausch + Lomb by 75.8% in the 4th quarter. Quadrature Capital Ltd now owns 48,258 shares of the company's stock valued at $824,000 after buying an additional 20,803 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Bausch + Lomb in the 4th quarter valued at approximately $1,195,000. FIL Ltd boosted its holdings in shares of Bausch + Lomb by 11.8% in the 4th quarter. FIL Ltd now owns 8,114,995 shares of the company's stock valued at $138,442,000 after buying an additional 855,250 shares during the last quarter. Barclays PLC boosted its holdings in shares of Bausch + Lomb by 5,588.6% in the 4th quarter. Barclays PLC now owns 10,467 shares of the company's stock valued at $179,000 after buying an additional 10,283 shares during the last quarter. Finally, Voloridge Investment Management LLC acquired a new stake in shares of Bausch + Lomb in the 4th quarter valued at approximately $188,000. Institutional investors own 11.07% of the company's stock.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief.